Cytosorb Therapy in Cardiac Surgery
- Conditions
- Cardiopulmonary SurgeryEndocarditisPeri-operative Cytokines Levels
- Registration Number
- NCT04309591
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 249
- patients with endocarditis undergoing cardiac surgery with cardio-pulmonary bypass circuit
- denial of consent for data use
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In-Hospital mortality during hospital stay for cardiac surgery from admission until discharge (approximately 15 days) In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption
- Secondary Outcome Measures
Name Time Method time in intensive care unit (days) during hospital stay for cardiac surgery from admission until discharge (approximately 15 days) time in intensive care unit (days)
In-Hospital time (days) hospital stay for cardiac surgery from admission until discharge (approximately 15 days) In-Hospital time (days)
Trial Locations
- Locations (1)
Klinik für Herzchirurgie, Universitätsspital Basel
🇨🇭Basel, Switzerland